The mortality of stroke in China has been decreasing in recent years owing to improvements in therapy and treatment [38, 39], such as the growing use of recombinant tissue-type plasminogen activator(r-tPA) and standard therapy. This evidence concerns the gene PLAT and stroke disorder.